Enanta Stock Plunges 14% After Wider Loss And Eczema Drug-Testing Delay

The royalty-funded drug developer also faces a leadership change, with its chief executive planning to retire by February 2027.

Share
Enanta Stock Plunges 14% After Wider Loss And Eczema Drug-Testing Delay

Enanta Pharmaceuticals, which develops drugs for viral and immune-related diseases, plunged 13.5% to $9.23 in Tuesday trading, as of 10:46 AM ET, losing $42 million in market value. The decline followed Monday's earnings release showing a wider quarterly loss, lower royalties and an eczema-drug testing delay the company blamed on manufacturing.

Royalties Fall, Losses Grow

The $15.1 million in revenue Enanta recorded a year earlier exceeded its fourth-quarter revenue of $12.9 million. Its net loss grew to $23.7 million from $18.7 million.

All of that quarterly revenue came from royalties on AbbVie's hepatitis C treatment. Enanta discovered glecaprevir, an antiviral used in the combination sold as MAVYRET in the United States and MAVIRET elsewhere. AbbVie sells the treatment in over 50 countries, and it has supplied substantially all of Enanta's royalty revenue since August 2017.

Enanta's earlier quarterly report showed revenue of $14.4 million and a $19.5 million net loss for the period ended June 30.

A Fourth Decline In Sight

ENTA shares were on pace for their fourth consecutive daily decline Tuesday. Enanta's market value stood at about $269 million in Tuesday trading.

The stock had already fallen 32% for the year at Monday's close, while the S&P 500 had gained 9%. Enanta also finished Monday 37% below its highest closing price of the past year.

Drug Tests And A CEO Transition

Chief Executive Jay R. Luly plans to retire by February 2027. Enanta promoted Tara L. Kieffer to chief operating officer.

The company's research includes two clinical-stage candidates for respiratory syncytial virus, or RSV. Its earlier-stage work includes oral treatments for type 2 inflammatory diseases, including chronic spontaneous urticaria and atopic dermatitis, a form of eczema.

Enanta held $188.9 million in cash, cash equivalents and short-term marketable securities as of September 30, 2025.

Enanta expects pediatric trial results for zelicapavir, its experimental RSV treatment, in the first quarter of 2027.

Sources

More on Enanta Pharmaceuticals

All Enanta Pharmaceuticals (ENTA) coverage →